Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients

The Company And Amgen Continue To Analyze GALACTIC-HF Results

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Detailed data for omecamtiv mecarbil at AHA show a slim overall benefit, but Cytokinetics highlighted its effects in sicker patients and investigators emphasized the drug’s impact on reduced hospitalizations.

Autumn red leaf with cut heart in a hand - Image
Cytokinetics highlighted a greater benefit from omecamtiv mecarbil treatment in patients with lower LVEF • Source: Shutterstock

Cytokinetics, Inc. and Amgen, Inc. previously reported that the Phase III GALACTIC-HF clinical trial of heart failure drug omecamtiv mecarbil met the primary endpoint but missed a key secondary endpoint and now the full results show that the overall benefit was modest. But while Cytokinetics sees a path forward in certain patients, Amgen has not determined whether this treatment benefit is worth pursuing further.

The detailed GALACTIC-HF results were presented at the American Heart Association (AHA) virtual annual meeting on 13 November. The trial...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D